Akari Therapeutics Plc
Akari Therapeutics is an oncology company developing antibody-drug conjugates (ADCs) with proprietary payloads designed to target cancer. Its lead payload, PH1, modulates RNA splicing and is intended to kill cancer cells and stimulate immune responses. Akari’s lead preclinical candidate, AKTX-101, targets the Trop-2 receptor and combines PH1 with a proprietary linker and antibody construct. Its discovery-stage AKTX-102 targets CEACAM5. The company also has legacy programs, including nomacopan, PAS-Nomacopan and PHP-303, which are not part of its active portfolio. Akari conducts drug discovery and development, relies on contract manufacturers for research and development materials, and is preparing AKTX-101 for clinical testing. It intends to seek partnerships by out-licensing rights to ADC candidates or PH1, and may establish or outsource sales, marketing and distribution if a product is approved. Akari is headquartered in Tampa, Florida.
No SEC Form 4 filings for $AKTX in the last 30 days.
See all $AKTX insider activity →Akari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On October 28, 2026, Akari Therapeutics, Plc (the “Company”) held a General Meeting (the “Special General Meeting”). Proxies were solicited pursuant to the Company’s Proxy Statement, filed with the Securities and Exc
Akari Therapeutics (AKTX) announced a presentation at the ADC Payload Summit, detailing preclinical findings of its RNA-splicing payload, PH1, which kills cancer cells and activates immunity. The company's lead candidate, AKTX-101, targets TROP2 and aims to start human trials in mid-2027. PH1 is designed to differentiate from traditional ADC payloads and has shown potential in preclinical studies.
Akari Therapeutics (AKTX) announced its lead drug, AKTX-101, is on track for Phase 1 trials in mid-2027. The company is advancing IND-enabling studies and GMP manufacturing, while exploring potential partnerships for its PH1 payload.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning AKTX (Akari Therapeutics Plc). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent AKTX coverage spans technology, corporate actions and financial news.
The authorized share increase creates dilution risk, likely pressuring the stock lower.
Preclinical results suggest a novel ADC mechanism that could boost investor interest.
The timeline extension provides a modest catalyst but is far in the future, limiting immediate price impact.
Compensation boost may signal confidence in management but unlikely to move the stock materially.
Compensation increase may be viewed as dilution risk and cost rise, potentially weighing on the stock.
AlphAI scores every news story that mentions AKTX with an AI model for sentiment and relevance, and aggregates insider trades from Akari Therapeutics Plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Akari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On October 28, 2026, Akari Therapeutics, Plc (the “Company”) held a General Meeting (the “Special General Meeting”). Proxies were solicited pursuant to the Company’s Proxy Statement, filed with the Securities and Exc
1 min readAkari Therapeutics (AKTX) announced a presentation at the ADC Payload Summit, detailing preclinical findings of its RNA-splicing payload, PH1, which kills cancer cells and activates immunity. The company's lead candidate, AKTX-101, targets TROP2 and aims to start human trials in mid-2027. PH1 is designed to differentiate from traditional ADC payloads and has shown potential in preclinical studies.
2 min readAkari Therapeutics (AKTX) announced its lead drug, AKTX-101, is on track for Phase 1 trials in mid-2027. The company is advancing IND-enabling studies and GMP manufacturing, while exploring potential partnerships for its PH1 payload.
1 min readAkari Therapeutics (AKTX) increased CEO Abizer Gaslightwala's base salary to $625,000, raised his bonus target to 55%, and granted options and RSUs. The changes were effective August 18, 2026, with the amendment entered on September 29, 2026. The company did not disclose reasons for the changes.
1 min readAkari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 29, 2026, Akari Therapeutics, Plc (the “ Company ”), entered into an amendment (the “ CEO Agreement Amendment
1 min readAkari Therapeutics (AKTX) filed a patent for its PH1 payload technology targeting cancer cells. The company plans to start a first-in-human trial for AKTX-101 by mid-2027. Preclinical studies showed promising results against various oncogenic drivers. AKTX is developing ADCs with RNA splicing-targeting payloads.
2 min readAkari Therapeutics (AKTX) filed a PCT patent application for its PH1 payload, which targets RNA splicing in cancers. The filing expands the company's intellectual property portfolio, covering PH1's ability to disrupt multiple cancer-driving pathways. Akari's CEO highlighted PH1's potential to impact angiogenesis, oncogene signaling, and programmed cell death, supporting its use across various cancer types.
2 min readAkari Therapeutics (AKTX) shares rose 50% after CEO highlighted preclinical data for its cancer treatment platform, AKTX-101, showing promise in pancreatic cancer models. The company plans to present data at the ASCO meeting in 2026 and begin Phase 1 trials in mid-2027. AKTX raised $5.5M in private financing. The stock is up 125% YTD.
2 min readU.S. stock indices S&P 500, Nasdaq 100, and Dow Jones hit record highs. Oil prices and Treasury yields eased on U.S.-Iran ceasefire hopes. April's PCE inflation data showed a 3.8% annual increase. IBM plans $10B quantum computing investment. SNOW surged on AWS partnership. LLY rose after CVS restored drug coverage. AKTX highlighted cancer treatment potential. CZR agreed to a $17.6B acquisition.
3 min readAkari Therapeutics reported a Q2 2026 net loss of $4.8M, up from $1.9M a year earlier, and said it ended June 30, 2026 with $7.7M cash. The company raised about $8.6M gross proceeds (about $8.0M net) via private placement and warrant exercises. Akari is advancing AKTX-101 toward a planned mid-2027 Phase 1 start.
1 min read
